First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations

Summary We developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) to rival nivolumab therapy which has received ethics approvals for a Phase 1 clinical trial in Australia. The US FDA granted Investigational New Drug approval to Imugene Ltd for clinical testing in NSCLC. We demonstrated synergistic vacci...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2021-07, Vol.125 (2), p.152-154
Main Authors: Guo, Linlin, Kaumaya, Pravin T. P.
Format: Article
Language:English
Subjects:
631/250/590/2030
631/67/1059/2325
Australia
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer Vaccines
Clinical trials
Comment
Drug Resistance
Epidemiology
Epitopes
Epitopes, B-Lymphocyte
ErbB-2 protein
Humans
Immune checkpoint
Lung cancer
Lung Neoplasms
Lymphocytes B
Molecular Medicine
Nivolumab
Non-small cell lung carcinoma
Oncology
PD-1 protein
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary We developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) to rival nivolumab therapy which has received ethics approvals for a Phase 1 clinical trial in Australia. The US FDA granted Investigational New Drug approval to Imugene Ltd for clinical testing in NSCLC. We demonstrated synergistic vaccine combinations with an HER-2 targeted vaccine (B-Vaxx).
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-021-01342-9